Immunocore (IMCR) Reports Positive Phase 1/2 Data for Brenetafusp in Advanced Melanoma

Immunocore Holdings (NASDAQ: IMCR) announced positive results from a Phase 1/2 clinical trial of its investigational drug brenetafusp in patients with advanced cutaneous melanoma on June 1, 2026. The data demonstrated meaningful anti-tumor activity and a manageable safety profile, supporting advancement into later-stage development. The company did not disclose specific efficacy percentages but confirmed the findings warrant a pivotal trial. Brenetafusp, a bispecific T-cell engager, targets the gp100 protein expressed in melanoma cells. Analysts note that if successful in confirmatory studies, the drug could become a new standard of care for patients who have progressed on existing immunotherapies. Shares of Immunocore moved higher in early trading following the announcement. The company plans to present the full data set at a medical conference later this year.